Related Experiment Video
Updated: Jun 4, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
SSCP and Sequence Analysis of p53 Mutations in Ovarian Tumors
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA.
Abstract:
The p53 tumor suppressor gene encodes a 53-kD nuclear phosphoprotein and is the most commonly altered gene in human cancers (1). There are a large variety of methods currently employed for detection of alterations in thep53 gene. The reported abnormalities in p53 have been detected with a variety of techniques including immunohistochemical staining (IHCS) as a primary screening modality and less frequently single-strand conformation polymorphism (SSCP) screening. However, certain mutations such as frameshift mutations may not be detectable by IHCS, and most studies using SSCP have limited their search to exons 5-8 (2). As shown previously by our lab, this strategy can lead to underreporting of the true frequency of p53 null mutations (3). We routinely perform a complete evaluation of the p53 open reading frame (exons 2-11) using SSCP analysis with an estimated sensitivity of over 90% (3). This approach significantly enhances the detection of null mutations, especially insertion/deletion type mutations.

